{"id":"oxaliplatin-oxal","safety":{"commonSideEffects":[{"rate":"60–90","effect":"Peripheral neuropathy (acute and chronic)"},{"rate":"70–80","effect":"Nausea and vomiting"},{"rate":"50–75","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"40–50","effect":"Diarrhea"},{"rate":"60–70","effect":"Fatigue"},{"rate":"2–5","effect":"Allergic reactions (including anaphylaxis)"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":{"setId":"7dc8dfb1-dec8-43b3-b2ea-05eac054b2c6","title":"OXALIPLATIN INJECTION, SOLUTION [NORTHSTAR RX LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxaliplatin is a third-generation platinum compound that binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription. Unlike earlier platinum agents, it has a unique diaminocyclohexane (DACH) ligand that confers activity against some platinum-resistant tumors. It is typically used in combination chemotherapy regimens such as FOLFOX (with fluorouracil and leucovorin).","oneSentence":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:42:41.462Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with 5-FU/leucovorin)"},{"name":"Adjuvant treatment of stage III colon cancer (in combination with 5-FU/leucovorin)"},{"name":"Advanced gastric cancer"},{"name":"Non-small cell lung cancer (in combination regimens)"}]},"trialDetails":[{"nctId":"NCT02008656","phase":"PHASE2","title":"Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Rectal Cancer","enrollment":358},{"nctId":"NCT00079274","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-02","conditions":"Adenocarcinoma of the Colon, Stage III Colon Cancer","enrollment":3397},{"nctId":"NCT01279681","phase":"PHASE3","title":"Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2011-01","conditions":"Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity","enrollment":32},{"nctId":"NCT00056030","phase":"PHASE2","title":"Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-12","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":73},{"nctId":"NCT00016952","phase":"PHASE2","title":"Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-04","conditions":"Colorectal Cancer","enrollment":19},{"nctId":"NCT00004190","phase":"PHASE2","title":"Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1999-10","conditions":"Pancreatic Cancer","enrollment":59},{"nctId":"NCT00026234","phase":"PHASE2","title":"Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-02","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases","enrollment":75},{"nctId":"NCT00005036","phase":"PHASE3","title":"Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-11","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":560},{"nctId":"NCT00016978","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-04","conditions":"Colorectal Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oxaliplatin (OXAL)","genericName":"Oxaliplatin (OXAL)","companyName":"Memorial Sloan Kettering Cancer Center","companyId":"memorial-sloan-kettering-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells. Used for Metastatic colorectal cancer (in combination with 5-FU/leucovorin), Adjuvant treatment of stage III colon cancer (in combination with 5-FU/leucovorin), Advanced gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}